Global AI-assisted Peptide Drug Discovery Platform Market Size is predicted to grow with a 14.1 % CAGR during the forecast period for 2025-2034.
An AI-assisted peptide drug discovery platform is a technology-driven system that integrates artificial intelligence (AI) with peptide chemistry, bioinformatics, and structural biology to accelerate and enhance the discovery and development of peptide-based therapeutics. Traditionally, peptide drug development begins with identifying peptide precursors, often derived from endogenous peptides produced naturally in the human body or from natural peptides found in the environment.
These precursors are then chemically or recombinantly modified and synthesized. Endogenous active polypeptides or proteins, despite being present in extremely small amounts, exhibit remarkably potent biological effects and often serve as natural lead molecules in the development of therapeutic agents. Many diseases are associated with imbalances in these endogenous peptides, making them valuable targets for drug development. AI enables the prediction of peptide structure and function, the identification of high-affinity peptide sequences for specific targets such as GPCRs, kinases, and ion channels, and the optimization of peptide properties, including stability, solubility, and permeability. By streamlining and enhancing these processes, AI platforms significantly reduce the time and cost associated with traditional peptide discovery pipelines.
AI platforms are particularly well-suited to address the complex biological mechanisms underlying inflammatory and autoimmune diseases, enabling the design of novel peptide therapeutics with enhanced specificity, efficacy, and safety. Conditions such as rheumatoid arthritis, psoriasis, inflammatory bowel disease (IBD), and multiple sclerosis affect millions worldwide, creating a strong demand for more targeted and effective treatments. Peptides are ideal therapeutic candidates in this space due to their ability to interact precisely with specific molecular pathways while minimizing off-target effects.
AI models, including generative AI and deep learning, are utilized to design peptides that modulate immune responses, such as inhibiting overactive T-cells or neutralizing disease-causing autoantibodies, by accurately predicting peptide binding to disease-specific targets. Moreover, AI can integrate patient-specific immunological and genetic data to design peptides tailored to individual immune profiles, supporting the growing trend of personalized therapies for autoimmune conditions.
Competitive Landscape
Some of the Major Key Players in the AI-assisted Peptide Drug Discovery Platform Market are:
- Peptilogics
- Pepticom
- Gubra
- Nuritas
- Aurigene
- Space Peptides
- Koliber Biosciences
- Cradle
- Insilico Medicine
- Fujitsu
Market Segmentation
The AI-assisted peptide drug discovery platform market is segmented based on application, therapeutic area, technology, end-user, and platform access model. Based on application, the market is segmented into drug design and optimization, hit identification and lead generation, target validation, and preclinical validation. Based on the therapeutic area, the market is divided into metabolic disorders, oncology, infectious diseases, neurological disorders, inflammatory and autoimmune diseases, and other areas. Based on technology, the market is divided into machine learning, deep learning, generative AI, natural language processing, and reinforcement learning. Based on end-user, the market is divided into pharmaceutical and biotechnology companies, contract research organizations, academic and research institutions, startups, and SMEs. Based on the platform access model, the market is divided into pipeline licensing, technology licensing, strategic alliances, library provider, and service provider
The Drug Design and Optimization Segment is Expected to Have the Highest Growth Rate During the Forecast Period
Based on application, the market is segmented into drug design and optimization, hit identification and lead generation, target validation, and preclinical validation. Among these, the drug design and optimization segment is expected to have the highest growth rate during the forecast period. The greatest strength of AI platforms lies in their ability to design novel peptide sequences with optimal physicochemical, biological, and pharmacokinetic properties. By leveraging advanced algorithms and predictive models, AI significantly accelerates the drug design cycle, enabling the rapid identification and refinement of lead candidates. These platforms can accurately predict structure-activity relationships (SAR), which helps in optimizing peptide interactions with biological targets. Additionally, AI enhances critical drug-like properties, such as stability, solubility, and bioavailability, while also minimizing immunogenicity, ultimately improving the likelihood of clinical success.
The Oncology Segment Dominates the Market
Based on the therapeutic area, the market is divided into metabolic disorders, oncology, infectious diseases, neurological disorders, inflammatory and autoimmune diseases, and other areas. Among these, the oncology segment dominates the market. Cancer remains one of the leading causes of death worldwide, fueling a strong demand for innovative and targeted therapies, including peptide-based drugs. Peptides offer high specificity and can be engineered to selectively bind to tumor-associated antigens and receptors such as HER2 and EGFR, minimizing off-target toxicity and improving treatment safety. AI-assisted platforms are increasingly being utilized to design tumor-targeting peptides, personalized cancer vaccines, and immune checkpoint modulators, significantly accelerating the development of next-generation oncology therapeutics.
North America Has the Largest Market Share During the Forecast Period.
North America is the market leader in the AI-assisted peptide drug discovery platform market due to The U.S. and Canada have a well-established life sciences ecosystem with a high concentration of biotech and pharmaceutical companies actively investing in peptide therapeutics and AI tools. Leading research institutions and universities play a critical role in driving early-stage innovation, particularly in computational biology and drug discovery. North America attracts the largest share of global biotech venture capital, with substantial funding directed toward AI-driven drug discovery initiatives. Government programs such as NIH funding and BARDA, along with robust private sector investments, continue to fuel advancements in peptide research. Additionally, the region is a global leader in AI, machine learning, and cloud computing technologies that are essential for the development and operation of AI-assisted peptide drug discovery platforms.
Recent Developments:
- In Jan 2025, Pepticom, declared that it had successfully raised $6.6 million in its Series A1 fundraising round. A large number of current investors participated in the round, which was led by Japan, Israel High Tech Ventures 2 LP. Pepticom's oral IL-17 inhibitor initiative, which aims to find better treatments for autoimmune illnesses, will advance more quickly thanks to this funding. This includes creating two classes of tiny, nanomolar, completely synthetic cyclic peptidomimetic inhibitors that target the IL-17A and IL-17F isoforms.
- In May 2023, Fujitsu and RIKEN declared the launch of their "Biodrug Design Accelerator," a platform for managing peptide drug discovery research operations, which is widely considered a promising area for novel drug development. A generative AI technology was developed by Fujitsu and RIKEN that uses a large number of electron microscopy projection images to accurately estimate the different forms of a target protein's conformation and their potential proportions. The technology also predicts conformational changes in the target protein based on the estimated proportions.
- In July 2022, Orion Biotechnology Canada Ltd and Peptilogics, a biotech company that engineers peptide therapeutics by combining biology and computation to improve the treatment landscape for patients with life-threatening diseases, and a drug discovery company that targets previously undrugged G Protein-Coupled Receptors (GPCRs) announced that they have entered into a research and development collaboration to leverage AI for drug discovery against an undrugged GPCR target.
AI-assisted Peptide Drug Discovery Platform Market Report Scope :
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 14.1 % from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Mn and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Application, By Therapeutic Area, By Technology, By End-User, By Platform Access Model and By Region. |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; South East Asia |
|
Competitive Landscape |
Peptilogics, Pepticom, Gubra, Nuritas, Aurigene, Space Peptides, Koliber Biosciences, Cradle, Insilico Medicine, Fujitsu |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
